For the quarter ending 2025-09-30, NVCR made $167,204,000 in revenue. -$37,270,000 in net income. Net profit margin of -22.29%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net revenues | 167,204,000 | 158,805,000 | 154,994,000 | 149,884,500 |
| Cost of revenues | 44,729,000 | 41,472,000 | 38,521,000 | 33,577,500 |
| Gross profit | 122,475,000 | 117,333,000 | 116,473,000 | 116,307,000 |
| Research, development and clinical studies | 54,029,000 | 55,833,000 | 53,777,000 | 51,404,000 |
| Sales and marketing | 58,546,000 | 57,066,000 | 55,792,000 | 61,308,500 |
| General and administrative | 45,921,000 | 43,955,000 | 44,769,000 | 56,006,500 |
| Total operating costs and expenses | 158,496,000 | 156,854,000 | 154,338,000 | 168,719,000 |
| Operating income (loss) | -36,021,000 | -39,521,000 | -37,865,000 | -52,412,000 |
| Financial income (expenses), net | 5,999,000 | 4,542,000 | 7,570,000 | 8,988,000 |
| Income (loss) before income tax | -30,022,000 | -34,979,000 | -30,295,000 | -43,424,000 |
| Income tax | 7,248,000 | 5,160,000 | 4,024,000 | 8,917,000 |
| Net income (loss) | -37,270,000 | -40,139,000 | -34,319,000 | -52,341,000 |
| Basic net income (loss) per ordinary share | -0.33 | -0.36 | -0.31 | -0.485 |
| Diluted net income (loss) per ordinary share | -0.33 | -0.36 | -0.31 | -0.485 |
| Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) | 111,908,252 | 111,572,191 | 110,281,832 | -54,056,816 |
| Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) | 111,908,252 | 111,572,191 | 110,281,832 | -54,056,816 |
NovoCure Ltd (NVCR)
NovoCure Ltd (NVCR)